Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Guillermo Garcia-Manero, MD, Pierre Fenaux, MD PhD, Aref Al-Kali, MD, Shyamala C. Navada, MD, Maria R. Baer, MD, Azra Raza, MD, Peter Greenberg, MD, Karl-Anton Kreuzer, MD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Gail J. Roboz, Valeria Santini, MD, Uwe Platzbecker, MD, Michael E. Petrone, MD MPH, Bernard Brownstein, MD, Patrick Simon Zbyszewski, MBA, Manoj Maniar, PhD, Lewis R. Silverman, MD

Blood (2016) 128 (22): 2011.

https://doi.org/10.1182/blood.V128.22.2011.2011

Published: 2016

Journal Articles

Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Andrea Kuendgen, MD, Heinz Tuechler, Meritxell Nomdedeu, MD, Detlef Haase, MD, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Francesc Sole, PhD, Mikkael A. Sekeres, MD MS, Matteo Giovanni Della Porta, MD, Alan F List, MD, Mario Cazzola, MD, Amy E. DeZern, MD MHS, Gail J. Roboz, David P. Steensma, MD, Arjan A. van de Loosdrecht, MD PhD, Richard F. Schlenk, MD, Xavier Calvo, MD, Sabine Blum, MD, Arturo Pereira, Arturo Pereira, Peter Valent, MD, Dolors Costa, Dolors Costa, Aristoteles Giagounidis, Aristoteles Giagounidis, Luis Benlloch, Uwe Platzbecker, MD, Carmen Pedro, MD, Michael Lübbert, MD, María Teresa Cedena, MD, Julie Schanz, MD, Sigrid Machherndl-Spandl, MD, Maria Lopez-Pavia, MD, María Díez-Campelo, MD, Claudia D. Baldus, MD, Montserrat Martínez de Sola, Reinhard Stauder, MD, Brayan Merchan, MD, Claudia Mende, Maria Teresa Voso, MD, Maria Teresa Voso, MD, Itziar Oiartzabal, Itziar Oiartzabal, Christina Ganster, PhD, Francesc Cobo, Thomas Schroeder, MD, Jordi Esteve, Rainer Haas, MD, Benet Nomdedeu, Peter Greenberg, MD, Ulrich Germing, Guillermo Sanz, MD

Blood (2016) 128 (22): 112.

https://doi.org/10.1182/blood.V128.22.112.112

Published: 2016

Journal Articles

Efficacy and Safety of Darbepoetin Alfa (DA) in Patients with Myelodysplastic Syndromes (MDS): A Systematic Review and Meta-Analysis

Sophie Park, MD PhD, Pierre Fenaux, MD PhD, Peter Greenberg, MD, Bhakti Mehta, MD MPH, Fiona Callaghan, PhD, Christopher Kim, PhD MPH, Dianne Tomita, PhD, Hairong Xu, MD PhD

Blood (2015) 126 (23): 5236.

https://doi.org/10.1182/blood.V126.23.5236.5236

Published: 2015

Journal Articles

Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age

Ehab Atallah, MD, Mary M. Horowitz, MD MS, Brent Logan, PhD, Min Chen, MS, Michael J. Boo, JD, Corey S Cutler, MD MPH, Joachim Deeg, MD, James L. Gajewski, MD, Dennis L. Confer, MD, Stephanie Farnia, MPH, Peter Greenberg, MD, Erica Warlick, MD, Daniel Weisdorf, MD, J. Douglas Rizzo, MD

Blood (2015) 126 (23): 193.

https://doi.org/10.1182/blood.V126.23.193.193

Published: 2015

Journal Articles

Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee

Blood (2015) 126 (23): 907.

https://doi.org/10.1182/blood.V126.23.907.907

Published: 2015

Journal Articles

Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes

Blood (2015) 126 (23): 2879.

https://doi.org/10.1182/blood.V126.23.2879.2879

Published: 2015

Journal Articles

Azacitidine Plus Lenalidomide for Untreated AML Patients Ineligible for Conventional Chemotherapy

Daniel A Pollyea, MD, James L. Zehnder, Steven Coutre, MD, Jason Gotlib, Leonel Gallegos, MD, Peter Greenberg, MD, Bing Zhang, MD, MS, Michaela Liedtke, MD, Ross L. Levine, Bruno C. Medeiros, MD

Blood (2012) 120 (21): 3575.

https://doi.org/10.1182/blood.V120.21.3575.3575

Published: 2012

Journal Articles

Effect of Romiplostim in Patients (pts) with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Azacytidine

Hagop Kantarjian, MD, Frank Giles, MD, Peter Greenberg, MD, Ronald Paquette, MD, Eunice Wang, MD, Janice Gabrilove, MD, Guillermo Garcia-Manero, MD, Julie Gray, Kuolung Hu, PhD, Janet Franklin, MD, MPH

Blood (2008) 112 (11): 224.

https://doi.org/10.1182/blood.V112.11.224.224

Published: 2008

Journal Articles

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

Blood (2008) 111 (2): 574–582.

https://doi.org/10.1182/blood-2007-06-096370

Published: 2008

Includes: Supplemental data

Journal Articles

Phase I/II, Randomized, MultiCenter, Dose-Ascension Study of the p38MAPK Inhibitor Scio-469 in Patients with Myelodysplastic Syndrome (MDS).

Lubomir Sokol, MD, PhD, Larry Cripe, M.D., Hagop Kantarjian, M.D., Mikkael A. Sekeres, M.D., Simrit Parmar, M.D., Peter Greenberg, M.D., Stuart Goldberg, M.D., Vikas Bhushan, M.D., Jamile Shammo, M.D., Raymond Hohl, M.D., Ph.D., Yu-Ping Li, Ph.D., Ann Lowe, M.D., Joy Zhu, M.D., Alan List, M.D.

Blood (2006) 108 (11): 2657.

https://doi.org/10.1182/blood.V108.11.2657.2657

Published: 2006

Journal Articles

Immunosuppressive Treatment Is Associated with Durable Responses and a Survival Advantage in Younger Patients with int-1 Myelodysplastic Syndrome.

Elaine M. Sloand, MD, Peter Greenberg, MD, Colin Wu, Ph.D, Neal S. Young, MD, John Barrett, MD

Blood (2005) 106 (11): 2519.

https://doi.org/10.1182/blood.V106.11.2519.2519

Published: 2005

Journal Articles

Phase III Prospective Randomized Trial of EPO with or without G-CSF Versus Supportive Therapy Alone in the Treatment of Myelodysplastic Syndromes (MDS): Results of the ECOG- CLSG Trial(E1996).

Kenneth B. Miller, MD, Haesook T. Kim, PhD, Peter Greenberg, MD, Richard van der Jagt, MD, John M. Bennett, MD, Martin S. Tallman, MD, Elisabeth Paietta, PhD, Gordon Dewald, PhD, Jessie G. Houston, MD, Mary Thomas, RN, MS, Jacob Rowe, MD

Blood (2004) 104 (11): 70.

https://doi.org/10.1182/blood.V104.11.70.70

Published: 2004

Journal Articles

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

Blood (2004) 104 (2): 579–585.

https://doi.org/10.1182/blood-2004-01-0338

Published: 2004

Journal Articles

Leukemic cell resistance: targeting needed beyond MDR-1

Peter Greenberg

Blood (2003) 102 (4): 1149.

https://doi.org/10.1182/blood-2003-06-1877

Published: 2003

Journal Articles

International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

Peter Greenberg, Christopher Cox, Michelle M. LeBeau, Pierre Fenaux, Pierre Morel, Guillermo Sanz, Miguel Sanz, Teresa Vallespi, Terry Hamblin, David Oscier, Kazuma Ohyashiki, Keisuke Toyama, Carlo Aul, Ghulam Mufti, John Bennett

Blood (1997) 89 (6): 2079–2088.

https://doi.org/10.1182/blood.V89.6.2079

Published: 1997

Journal Articles

Alterations of Granulopoiesis Following Chemotherapy

Peter Greenberg, Ine Bax, Beth Mara, Stanley Schrier

Blood (1974) 44 (3): 375–383.

https://doi.org/10.1182/blood.V44.3.375.375

Published: 1974

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Efficacy and Safety of Darbepoetin Alfa (DA) in Patients with Myelodysplastic Syndromes (MDS): A Systematic Review and Meta-Analysis

Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age

Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee

Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes

Azacitidine Plus Lenalidomide for Untreated AML Patients Ineligible for Conventional Chemotherapy

Effect of Romiplostim in Patients (pts) with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Azacytidine

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

Phase I/II, Randomized, MultiCenter, Dose-Ascension Study of the p38MAPK Inhibitor Scio-469 in Patients with Myelodysplastic Syndrome (MDS).

Immunosuppressive Treatment Is Associated with Durable Responses and a Survival Advantage in Younger Patients with int-1 Myelodysplastic Syndrome.

Phase III Prospective Randomized Trial of EPO with or without G-CSF Versus Supportive Therapy Alone in the Treatment of Myelodysplastic Syndromes (MDS): Results of the ECOG- CLSG Trial(E1996).

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

Leukemic cell resistance: targeting needed beyond MDR-1

International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

Alterations of Granulopoiesis Following Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only